Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis

Patrik Stolt,1 Abqariyah Yahya,1,2 Camilla Bengtsson,1 Henrik Källberg,1 Johan Rönnelid,3,4 Ingvar Lundberg,5 Lars Klareskog,4 Lars Alfredsson1; the EIRA Study Group

ABSTRACT

Objectives To study the association between silica exposure, separately as well as combined with smoking, and the risk of developing rheumatoid arthritis (RA) with or without the presence of antibodies against citrullinated peptide antigens (ACPA).

Methods This Swedish population based case–control study analysed 577 incident RA cases and 659 randomly selected controls, all men aged 18–70 years, included during May 1996 to May 2006. Self-reported silica exposure, defined as exposure to stone dust, rock drilling or stone crushing and cigarette smoking was registered. ACPA status among cases was analysed.

Results Silica-exposed subjects were found to have a moderately increased risk of ACPA-positive RA (odds ratio (OR) adjusted for age and residency=1.67 (95% CI 1.13 to 2.48), but not of ACPA-negative RA (OR=0.98 (95% CI 0.57 to 1.66)), compared with subjects unexposed to silica. Subjects exposed to rock drilling were found to have a somewhat more markedly increased risk of ACPA-positive RA (OR=2.34 (95% CI 1.17 to 4.68)). A high risk of developing ACPA-positive RA was observed among silica-exposed current smokers (OR=7.36 (95% CI 3.31 to 16.38)), exceeding the risk expected from the separate effects of silica exposure and current smoking, indicating an interaction between these exposures (attributable proportion due to interaction=0.60 (95% CI 0.26 to 0.95)).

Conclusion Silica exposure combined with smoking among men is associated with an increased risk of developing ACPA-positive RA. These results suggest that different inhalation exposures may interact in the aetiology of ACPA-positive RA.

INTRODUCTION

The association between smoking and development of rheumatoid arthritis (RA)1–6 is the most recognised link between the environment and the aetiology of this disease and was subsequently found to be confined to the subset of RA defined by the presence of antibodies to citrullinated peptides (ACPA).6 Interaction between smoking and the most recognised, non-sex-linked, genetic risk factor of RA—that is, the HLA-DRB1 ‘shared epitope’ (SE)7 for the risk of developing ACPA-positive RA, has been described.6 8–11 Exposure to crystalline silica is another well-defined inhalation exposure, reported, for example, from industries involving mining, construction, ceramics, glass, agriculture, but also from branches such as electronics. It is commonly occurring globally, although exposure levels in Western industries, in general, have decreased during recent decades.12–15 Silica exposure has been observed to be linked to RA and other immunologically mediated diseases.16–19 and our group found that it was associated with an about twofold increased risk of developing RA overall, also when smoking was considered as a potential confounder.19 In that study, silica-exposed ever-smokers were found to have an increased risk of RA, statistically significant for the rheumatoid factor-positive, but not the rheumatoid factor-negative, subset of the disease. The small number of silica-exposed never-smokers left the corresponding results for that category inconclusive. Results compatible with an interaction between silica exposure and smoking transpired, but were regarded with caution owing to the small number of silica-exposed never-smokers.19

No previous study available in PubMed, however, has described the link between silica exposure, separately or combined with smoking or SE, and the risk of developing RA of different ACPA status. This study aimed at investigating these issues, as they are of interest for an understanding of the mechanisms linking silica exposure, in particular, and air borne agents, in general, to the development of RA and for the discussions about preventive measures against the disease.

MATERIALS AND METHODS

This study is based on EIRA (Epidemiological Investigation of RA), which is a case–control study comprising the general population, aged 18–70 years, of a geographically defined part of Sweden. The present study analysed 577 male cases and 659 male controls included during May 1996 to May 2006, but none of the female study subjects.

The study was approved by the regional committee on ethics at Karolinska Institutet, Stockholm, Sweden.

Case definition and identification

A case was defined as a person in the study base with newly developed RA, defined according to the American College of Rheumatology criteria.20 All potential cases were evaluated by a rheumatologist. Twenty-one units, including all public rheumatology units and almost all privately run units in the study area, reported cases.21 Initially, subjects with undifferentiated arthritis were also included, in order to investigate a broader spectrum of arthritis. These 57 subjects were excluded from this study.
Selection of controls
The selection of controls aimed at achieving a control group with a distribution of exposures reflecting that of the study base, but with consideration taken of the age, gender and residency of the case group. For each case, a control was randomly selected from the study base with consideration taken of age, gender and residency, using the national population register, which is continuously updated. If a control did not participate, a new control was selected using the same principles. In order to increase power, the male controls selected to match the subjects with undifferentiated arthritis were retained in the study, despite the exclusion of the corresponding case group.

Data collection
Exposure data were self-reported by subjects included in the study using a questionnaire. Completed questionnaires were obtained from 95% of the case group and 81% of the controls.

Exposures
The questionnaire explores individual, demographic and environmental factors, including occupational exposures during different time periods. The realisation of the first joint swelling was used as an estimate of disease onset for each case and the year of that first swelling was defined as the index year. The same index year was used for the corresponding control. Only exposure data up to the index year were analysed. Subjects exposed to rock drilling, stone crushing or stone dust during the index year or before, were classified as silica exposed.

Rock drilling and stone crushing have previously been found to be associated with a high degree of silica exposure. Doses of silica exposure were not estimated in this study, however, as no results from hygienic measurements were available.

Cigarette smokers were categorised as current smokers if they had regularly smoked during the index year, as ex-smokers if they had smoked before, but not during, the index year and as ever-smokers if they had smoked during or before the index year. People who had never smoked during or before the index year were defined as never-smokers.

Potential confounders
Age, residential area, social class, joint injury and physical work load were considered as potential confounders. Age was categorised into 10 strata. The occupation during the index year was used as a marker for social class. Physical work load was classified using eight alternatives, ranging from ‘not demanding at all’ to ‘very, very demanding’. Joint injury was defined as any joint injury requiring medical attention.

Analyses of ACPA
ACPA were identified and quantified with Immunocan-RA Mark2 ELISA test (anti-CCP2 test). An antibody level >25 AU/ml was regarded as ACPA positivity.

Genotyping
Genotyping for SE alleles, defined as DRB1*01, *04 and *10 of the HLA-DRB1 gene, was conducted by SSP-PCR. People carrying one or two SE alleles were classified as having any SE alleles.

Statistical analyses
Silica-exposed subjects were compared with subjects unexposed to silica, and subjects with different combinations of silica-exposure status, smoking habits and SE status, were compared for the incidence of ACPA-positive RA, ACPA-negative RA, and RA overall, by calculating odds ratio (OR) with 95% CI using unconditional regression analysis. Matched analyses using conditional regression analysis were also conducted, the results of which are not presented, as they generally agreed with those of the unmatched analyses, but had lower precision. Odds ratios were adjusted for potential confounding from age and residential area. Adjustment for social class, joint injury and physical work load was also conducted, but only marginally changed the estimates and was not retained in the final analyses. Adjustment for potential confounding from smoking was not conducted, as this was contraindicated by results suggesting an interaction between smoking and silica exposure.

Odds ratios were interpreted as relative risks as the study was population based and the controls were a random sample from the study base and as the participation proportion was high.

The interactions between silica exposure and smoking and between silica exposure and SE, were analysed using departure from additivity of effects as criterion of interaction and were quantified by calculating ‘attributable proportion (AP) due to interaction’ with 95% CI. AP is the proportion of the incidence among individuals exposed to two interacting risk factors that is attributable to the interaction itself (ie, reflecting their combined effect beyond the sum of their independent effects).

All analyses were performed using the Statistical Analysis System (SAS) version 9.1.

RESULTS
Characteristics of the study group
In this study, 577 cases and 659 controls were analysed. The proportion of silica-exposed subjects was 14% among the cases and 10.5% among the controls. The proportion of ACPA-positive subjects was 67.5% among silica-exposed cases and 55% among cases unexposed to silica. The proportion of ever-smokers was 70% among silica-exposed cases, 60% among cases unexposed to silica, 59% among silica-exposed controls and 49% among controls unexposed to silica.

Silica exposure
Silica-exposed subjects (30 cases, 69 controls) were found to have a moderately increased risk of developing ACPA-positive RA, with an OR adjusted for age and residency of 1.67 (95% CI 1.13 to 2.48), but no increased risk of developing ACPA-negative RA (OR=0.98 (95% CI 0.57 to 1.66)), compared with subjects unexposed to silica (table 1).

Subjects exposed to rock drilling (26 cases, 17 controls), regarded as highly exposed to silica, were found to have a somewhat more marked increase in the risk of developing ACPA-positive RA (OR adjusted for age and residency=2.34 (95% CI 1.17 to 4.68), but no increased risk of developing ACPA-negative RA (OR=0.96 (95% CI 0.34 to 2.67)), compared with subjects unexposed to silica (table 1).

Cigarette smoking
Among subjects unexposed to silica, an increased risk of ACPA-positive RA was observed among ever-smokers (OR=2.55 (95% CI 1.72 to 3.72)), current smokers (OR=2.78 (95% CI 1.77 to 4.38)) and among ex-smokers (OR=2.52 (95% CI 1.63 to 3.89)), compared with never-smokers unexposed to silica (table 2).
Silica exposure and cigarette smoking combined

Current cigarette smokers who were silica exposed were found to have a pronounced increase in the risk of ACPA-positive RA compared with never-smokers unexposed to silica (OR=7.36 (95% CI 3.31 to 16.38)) (table 2). The corresponding result was 2.78 (95% CI 1.77 to 4.38) for current cigarette smokers unexposed to silica and 1.15 (95% CI 0.42 to 3.15) for never-smokers exposed to silica (table 2). The relative risk of ACPA-positive RA for current cigarette smokers exposed to silica thus exceeds the risk expected from the separate effects of silica exposure and current smoking, indicating an interaction between these exposures. The AP was estimated at 0.60 with a 95% CI of 0.26 to 0.95, indicating that this interaction is statistically significant (table 3).

Current cigarette smokers with more than 20 pack-years who were silica exposed, were observed to have an even more markedly increased risk of ACPA-positive RA (OR=14.19 (95% CI 5.32 to 37.84)), and a high AP (0.74 (95% CI 0.48 to 1.00)) (data not shown).

When current smoking was replaced with ever-smoking, the risk of ACPA-positive RA fell somewhat, but was still distinctly increased (OR=4.08 (95% CI 2.31 to 7.21)) (table 2), while the AP was reduced and no longer statistically significant (AP=0.34 (95% CI –0.09 to 0.77)) (table 3). No indication of an interaction between ex-smoking and silica exposure transpired (AP=0.02 (95% CI 0.77 to 0.81)) (table 3).

Silica exposure and SE combined

Silica-exposed subjects carrying any SE allele were observed to have increased risk of ACPA-positive RA, compared with subjects unexposed to silica without SE alleles, OR=11.39 (95% CI 5.10 to 22.07). The corresponding result was 7.86 (95% CI 5.10 to 12.12) for subjects unexposed to silica carrying any SE allele and 2.51 (95% CI 0.97 to 6.49) for silica-exposed subjects without SE alleles (table 4). The AP, however, remained inconclusive (0.18 (0.33 to 0.68)).

DISCUSSION

The risk of developing ACPA-positive RA was observed to be just above 1.5-fold increased among subjects exposed to silica overall and almost 2.5-fold increased among subjects exposed to rock drilling; neither group was found to have any increase in the risk of developing ACPA-negative RA, compared with subjects unexposed to silica (table 1). Silica-exposed current smokers were observed to have a more than sevenfold increase in the risk of ACPA-positive RA, exceeding the risk expected from the separate effects of silica exposure and smoking, suggesting that an interaction between these exposures contributes to development of ACPA-positive RA.

As an interaction between smoking and SE for the risk of ACPA-positive RA was previously observed,6–11 we investigated the potential of an analogous interaction between silica exposure and SE. The result of this analysis (AP=0.18 (95% CI 0.33 to 0.68)), however, remained inconclusive owing to limited power, although it may be regarded as compatible with a slight tendency towards an interaction. The pattern was similar when the analysis was restricted to never-smokers.

This study is, to our knowledge, the first to observe that the association between silica exposure and the risk of developing RA is combined with ACPA positivity and extends thereby previously presented results.19 Furthermore, the combined effect of silica exposure and cigarette smoking, described in this study, is the first observation in which two environmental exposures appear to interact synergistically as susceptibility factors for ACPA-positive RA.

Table 1 Odds ratio (OR) with 95% CI of developing ACPA-positive RA, ACPA-negative RA and RA overall, respectively, among men exposed to stone dust, rock drilling, stone crushing and silica overall, respectively, compared with men unexposed to silica

<table>
<thead>
<tr>
<th>Exposure</th>
<th>Category of RA</th>
<th>Number of cases/exposed controls</th>
<th>OR*</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stone dust</td>
<td>ACPA-positive RA</td>
<td>44/58</td>
<td>1.60</td>
<td>1.04 to 2.44</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>17/58</td>
<td>1.02</td>
<td>0.57 to 1.82</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>67/58</td>
<td>1.38</td>
<td>0.95 to 2.02</td>
</tr>
<tr>
<td>Rock-drilling</td>
<td>ACPA-positive RA</td>
<td>18/17</td>
<td>2.34</td>
<td>1.17 to 4.68</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>5/17</td>
<td>0.96</td>
<td>0.34 to 2.67</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>26/17</td>
<td>1.83</td>
<td>0.97 to 3.43</td>
</tr>
<tr>
<td>Stone crushing</td>
<td>ACPA-positive RA</td>
<td>11/13</td>
<td>2.03</td>
<td>0.88 to 4.67</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>5/13</td>
<td>1.34</td>
<td>0.45 to 3.97</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>17/13</td>
<td>1.62</td>
<td>0.77 to 3.43</td>
</tr>
<tr>
<td>Silica overall</td>
<td>ACPA-positive RA</td>
<td>54/69</td>
<td>1.67</td>
<td>1.13 to 2.48</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>20/69</td>
<td>0.98</td>
<td>0.57 to 1.66</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>60/69</td>
<td>1.39</td>
<td>0.98 to 1.96</td>
</tr>
</tbody>
</table>

*OR adjusted for the potential confounding from age and residential area.
ACPA, antibodies against citrullinated peptide antigens; RA, rheumatoid arthritis.

Table 2 Odds ratio (OR) with 95% CI of developing ACPA-positive RA, ACPA-negative RA and RA overall, respectively, among men with different combinations of silica exposure status and cigarette smoking, compared with men who were unexposed to silica and never-smokers

<table>
<thead>
<tr>
<th>Smoking category</th>
<th>Category of RA</th>
<th>Subjects unexposed to silica</th>
<th>Subjects exposed to silica</th>
<th>Number of cases/controls</th>
<th>OR*</th>
<th>95% CI</th>
<th>Number of cases/controls</th>
<th>OR*</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never-smokers</td>
<td>ACPA-positive RA</td>
<td>57/193</td>
<td>1</td>
<td>6/17</td>
<td>1.15</td>
<td>0.42 to 3.15</td>
<td>5/193</td>
<td>1</td>
<td>0.85 to 2.75</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>54/193</td>
<td>1</td>
<td>4/17</td>
<td>0.85</td>
<td>0.26 to 2.75</td>
<td>4/193</td>
<td>1</td>
<td>0.37 to 1.98</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>25/193</td>
<td>1</td>
<td>10/17</td>
<td>0.86</td>
<td>0.37 to 1.98</td>
<td>10/17</td>
<td>1</td>
<td>0.37 to 1.98</td>
</tr>
<tr>
<td>Ever-smokers</td>
<td>ACPA-positive RA</td>
<td>176/284</td>
<td>2.53</td>
<td>38/41</td>
<td>4.08</td>
<td>2.31 to 7.21</td>
<td>38/41</td>
<td>4.08</td>
<td>2.31 to 7.21</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>101/284</td>
<td>1.23</td>
<td>13/41</td>
<td>1.16</td>
<td>0.56 to 2.39</td>
<td>13/41</td>
<td>1.16</td>
<td>0.56 to 2.39</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>297/284</td>
<td>1.69</td>
<td>56/41</td>
<td>2.35</td>
<td>1.46 to 3.80</td>
<td>56/41</td>
<td>2.35</td>
<td>1.46 to 3.80</td>
</tr>
<tr>
<td>Ex-smokers</td>
<td>ACPA-positive RA</td>
<td>99/174</td>
<td>2.52</td>
<td>17/28</td>
<td>2.84</td>
<td>1.39 to 5.84</td>
<td>17/28</td>
<td>2.84</td>
<td>1.39 to 5.84</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>57/174</td>
<td>1.03</td>
<td>9/28</td>
<td>1.05</td>
<td>0.45 to 2.46</td>
<td>9/28</td>
<td>1.05</td>
<td>0.45 to 2.46</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>171/174</td>
<td>1.58</td>
<td>28/28</td>
<td>1.71</td>
<td>0.94 to 3.08</td>
<td>28/28</td>
<td>1.71</td>
<td>0.94 to 3.08</td>
</tr>
<tr>
<td>Current smokers</td>
<td>ACPA-positive RA</td>
<td>77/110</td>
<td>2.78</td>
<td>21/13</td>
<td>7.36</td>
<td>3.31 to 16.38</td>
<td>21/13</td>
<td>7.36</td>
<td>3.31 to 16.38</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>44/110</td>
<td>1.43</td>
<td>4/13</td>
<td>1.16</td>
<td>0.35 to 3.87</td>
<td>4/13</td>
<td>1.16</td>
<td>0.35 to 3.87</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>126/110</td>
<td>1.85</td>
<td>28/13</td>
<td>3.64</td>
<td>1.78 to 7.46</td>
<td>28/13</td>
<td>3.64</td>
<td>1.78 to 7.46</td>
</tr>
</tbody>
</table>

*OR adjusted for the potential confounding from age and residential area.
ACPA, antibodies against citrullinated peptide antigens; RA, rheumatoid arthritis.
The interaction between silica exposure and smoking and between silica exposure and SE was analysed using departure from additivity of effects as the criterion of interaction. This was described as the most appropriate approach for identifying ‘biological interactions’ by Rothman et al., who introduced the ‘pie model’ to explain risk in which two risk factors are either independent (ie, no pathway to disease requires involvement of both) or have biological interaction (ie, at least one pathway towards disease requires the involvement of both). He demonstrated algebraically, based on disease rates connected to the pie model that independent risk factors adhere to an additive model and that biological interaction results in departure from additivity of the disease rates. Therefore, the empirical criterion when assessing biological interaction is based on whether or not disease rates are additive. This criterion stems from a basic, but general, definition of biological interaction which is highly relevant for the search of disease mechanisms. The product term in a logistic regression model does, in general, not allow such a specific biological interpretation.

In the primary assessment of the combined effect of silica exposure and smoking, ever exposure to silica and current smoking was analysed. The reason for this is that people ever exposed to crystalline silica may be regarded as potentially exposed to silica particles indefinitely as it has been found previously that silica particles may remain in lung tissues permanently, whereas cigarette smoke contains numerous components with different characteristics and the impact of smoking on the risk of RA has been found to eventually disappear after smoking cessation.

The conclusiveness of the results for the association between silica exposure and smoking on the risk of RA has been found to eventually disappear after smoking cessation. The increased risk of developing ACPA-positive, but not ACPA-negative RA, among silica-exposed subjects, described in this article, is analogous to the results we obtained among smokers in a previous study, in which citrullinated proteins in alveolar immune cells of smokers were also observed. Hypothetically, a common feature of silica exposure and smoking may be a link to citrullination of peptides, which when engulfed and presented by antigen-presenting cells may induce an immunological response against citrullinated antigens, which might contribute to the development of RA. Of interest in this context are the previous observations linking silica exposure to apoptosis, during which citrullination may occur and to the development of antibodies against apoptotic cells in animal models.

This together with the fact that disturbed apoptosis has been suggested as being a pathogenic factor in smoking-related pulmonary diseases might hypothetically explain some part of the combined effect of silica exposure and smoking, observed in this study. This and other evidence that immunological tolerance against citrullinated proteins/peptides may be broken by exposure of the respiratory tract to exogenous agents, deserves further study.

The results of our study, which suggest an interaction between silica exposure and smoking in the development of ACPA-positive RA, underline the importance of considering environmental factors in combination, as well as potential interactions between the environment and genetic polymorphisms in epidemiological studies. These results also provide information about silica exposure and smoking in any discussion about preventive measures against RA, and suggest that smoking potentially interacts with other environmental exposures in the aetiology of the ACPA-positive subset of this disease.

### Table 3

**Attributable proportion (AP) due to interaction between ever-cigarette smoking, ex-cigarette smoking and current cigarette smoking, respectively, and silica exposure, associated with the risk of developing ACPA-positive RA and RA overall, respectively, with 95% CI**

<table>
<thead>
<tr>
<th>Smoking category</th>
<th>Category of RA</th>
<th>Subjects exposed to silica</th>
<th>Number of cases/controls</th>
<th>AP</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ever-cigarette smoking</td>
<td>ACPA-positive RA</td>
<td>38/41</td>
<td>0.34</td>
<td>−0.09 to 0.77</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>56/41</td>
<td>0.34</td>
<td>−0.09 to 0.77</td>
<td></td>
</tr>
<tr>
<td>Ex-cigarette smoking</td>
<td>ACPA-positive RA</td>
<td>17/28</td>
<td>0.02</td>
<td>−0.77 to 0.81</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>28/28</td>
<td>0.14</td>
<td>−0.53 to 0.81</td>
<td></td>
</tr>
<tr>
<td>Current cigarette smoking</td>
<td>ACPA-positive RA</td>
<td>21/13</td>
<td>0.60</td>
<td>0.26 to 0.95</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>28/13</td>
<td>0.52</td>
<td>0.12 to 0.93</td>
<td></td>
</tr>
</tbody>
</table>

ACPA, antibodies against citrullinated peptide antigens; RA, rheumatoid arthritis.

### Table 4

**Odds ratio (OR) with 95% CI of developing ACPA-positive RA, ACPA-negative RA and RA overall, respectively, among men with different combinations of silica exposure status and HLA-DRB1 ‘shared epitope’ (SE) status, compared with men unexposed to silica who were not carrying SE**

<table>
<thead>
<tr>
<th>SE status</th>
<th>Category of RA</th>
<th>Number of cases/controls</th>
<th>OR*</th>
<th>95% CI</th>
<th>Number of cases/controls</th>
<th>OR*</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>No SE</td>
<td>ACPA-positive RA</td>
<td>35/165</td>
<td>1</td>
<td>–</td>
<td>8/16</td>
<td>2.51</td>
<td>0.97 to 6.49</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>80/165</td>
<td>1</td>
<td>–</td>
<td>6/16</td>
<td>0.84</td>
<td>0.31 to 2.27</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>119/165</td>
<td>1</td>
<td>–</td>
<td>14/16</td>
<td>1.32</td>
<td>0.61 to 2.86</td>
</tr>
<tr>
<td>Any SE</td>
<td>ACPA-positive RA</td>
<td>238/142</td>
<td>7.86</td>
<td>5.10 to 12.12</td>
<td>48/21</td>
<td>11.39</td>
<td>5.10 to 22.07</td>
</tr>
<tr>
<td></td>
<td>ACPA-negative RA</td>
<td>103/142</td>
<td>1.52</td>
<td>1.04 to 2.23</td>
<td>13/21</td>
<td>1.48</td>
<td>0.67 to 3.20</td>
</tr>
<tr>
<td></td>
<td>RA overall</td>
<td>368/142</td>
<td>3.54</td>
<td>2.59 to 4.83</td>
<td>63/21</td>
<td>4.45</td>
<td>2.53 to 7.83</td>
</tr>
</tbody>
</table>

*OR adjusted for the potential confounding from age and residential area. ACPA, antibodies against citrullinated peptide antigens; RA, rheumatoid arthritis.

**Extended report**

Extended report

EIRA Study Group Goran Lindahl, Danderyd Hospital; Bert Svedrup, Eskilstuna Hospital; Helena Hellström, Falu lasaret; Tomas Weitoff, Gävle Hospital; Bengt Lindell, Kalmar Hospital; Birgitta Nordmark, Johan Bhar and Ingård Hafström, Karolinska University Hospital; Ido Leden, Kristianstad Hospital; Björn Lofström, Katrineholm Hospital; Ann Bengtsson and Thomas Skogh, Linköping hospital; Elisabeth Lindqvist, Lund University Hospital; Lennart Jacobsson, Malmö University Hospital; Kjell Huddén, Rheumatology Clinic in Stockholm City; Christin Lindström, Sophiahemmet; Annika Teleman, Spenshult Hospital; Eva Baecklund and Ann Knight, Uppsala University Hospital; Olle Svernell, Västervik Hospital.

Acknowledgements We would like to express our appreciation to Marie-Louise Siera and Lena Nise for excellent assistance in the collection of data.

Competing interests None.

Funding The study was supported by grants from the Swedish Medical Research Council, from the Swedish Council for Working life and Social Research, from King Gustaf V’s 80-year foundation, from the Swedish Rheumatism Association, from Stockholm County Council, from the insurance company AFA and from NIH (P60 AR40776).

Ethics approval This study was conducted with the approval of the regional committee on ethics at Karolinska Institutet, Stockholm, Sweden.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis

Patrik Stolt, Abqariyah Yahya, Camilla Bengtsson, Henrik Källberg, Johan Rönnelid, Ingvar Lundberg, Lars Klareskog, Lars Alfredsson and the EIRA Study Group

Ann Rheum Dis 2010 69: 1072-1076 originally published online December 4, 2009
doi: 10.1136/ard.2009.114694

Updated information and services can be found at:
http://ard.bmj.com/content/69/6/1072

These include:

References
This article cites 34 articles, 2 of which you can access for free at:
http://ard.bmj.com/content/69/6/1072#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Editor's choice (165)
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)
- Epidemiology (1407)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/